CliffBio
biologic

Strensiq

asfotase alfa

Loss of exclusivityOctober 2027projected — 12-year biologic exclusivity estimate
CompanyAlexion Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameStrensiq
Active ingredientasfotase alfa
Strength40MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2015
Marketing statusRx

More from Alexion Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Strensiq patent cliff — loss of exclusivity October 2027 | CliffBio